Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,794 JPY | +0.21% | +1.09% | +27.19% |
Apr. 25 | Chugai Pharmaceutical's Parent Roche Logs Lower Q1 Sales; Stock Falls 5% | MT |
Apr. 23 | Shimano’s Attributable Profit Jumps 17.2% in Fiscal Q1 | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 32.07 and 31.81 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Financial & Commodity Market Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.19% | 12.54B | C+ | ||
+0.16% | 75.94B | B | ||
+12.06% | 21.7B | C+ | ||
+39.83% | 8.36B | C+ | ||
-0.13% | 7.96B | B- | ||
+44.53% | 5.21B | C | ||
-2.16% | 2.96B | C+ | ||
-5.45% | 1.69B | C | ||
+15.14% | 1.29B | - | ||
+74.10% | 1.28B | - | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 8697 Stock
- Ratings Japan Exchange Group, Inc.